Kim Theilgaard-Mønch
Clinical Associate Professor, Group leader
Department of Clinical Medicine
Blegdamsvej 9, 2100 København Ø
Theilgaard Group
Ole Maaløes Vej 5
2200 København N.
Member of:
ORCID: 0000-0002-4239-4939
1 - 2 out of 2Page size: 10
- 2019
- Published
Identification of two distinct pathways of human myelopoiesis
Drissen, R., Thongjuea, S., Theilgaard-Mønch, Kim & Nerlov, C., 2019, In: Science immunology. 4, 35, eaau7148.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML
Jakobsen, J. S., Laursen, L. G., Schuster, Mikkel Bruhn, Pundhir, Sachin, Schoof, E., Ge, Y., d'Altri, T., Vitting-Seerup, K., Rapin, N., Gentil, C., Jendholm, J., Theilgaard-Mønch, Kim, Reckzeh, K., Bullinger, L., Döhner, K., Hokland, P., Fitzgibbon, J. & Porse, Bo Torben, 2019, In: Science Advances. 5, 7, p. 1-16 16 p., eaaw4304.Research output: Contribution to journal › Journal article › Research › peer-review
ID: 3997971
Most downloads
-
2501
downloads
HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
80
downloads
Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
39
downloads
Phosphorylation of SHP2 at Tyr62 enables acquired resistance to SHP2 allosteric inhibitors in FLT3-ITD-driven AML
Research output: Contribution to journal › Journal article › Research › peer-review
Published